Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of ...
argenx SE has achieved rapid commercial success with VYVGART, driving $4.2 billion in 2025 sales and operational profitability. VYVGART's ongoing US MG penetration and label expansions, including ...
Regionally, North America leads the Global Plasma Fractionation Market, accounting for approximately 54% of the total market share in 2026. The region's dominance is supported by well-established plas ...
Investing.com - Raymond James upgraded Dianthus Therapeutics (NASDAQ:DNTH) to Strong Buy from Outperform on Tuesday and raised its price target to $123 from $63. The stock surged 43% over the past ...
NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to ...
We recently compiled a list of the Top 10 Boring Stocks That Make Money. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the most boring stocks. TheFly reported on March 12 that Wedbush raised its ...
Brian is a New York–based science and health journalist. His work has been published by The Atlantic, The Paris Review, The New York Times For Kids, CBS News, The TODAY Show, Barron's PENTA, Engadget, ...
Resting and staying hydrated helps support recovery from acute bronchitis. Chronic bronchitis requires ongoing medical care for long-term symptoms. Antibiotics can treat bacterial bronchitis, but not ...
The following slide deck was published by Dianthus Therapeutics, Inc. in conjunction with this event.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results